Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib

Journal of Surgical Oncology

Volumn 104, Issue 8, 2011, Pages 901-906

  Kim, Edward J ^a   Zalupski, Mark M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

GIST; KIT PDGFR; tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; BMS 3548245; DASATINIB; IMATINIB; MASITINIB; MOTESANIB; NILOTINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB;

ADVANCED CANCER; ARTICLE; DIARRHEA; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEUKOPENIA; ONCOGENE C KIT; POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; THIAZOLES;

EID: 80855130388     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21872     Document Type: Article

References (45)

1. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580. (Pubitemid 28067289)
2. Blanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632. (Pubitemid 351264358)
3. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004; 364: 1127-1134. (Pubitemid 39296599)
4. Maleddu A, Pantaleo MA, Nannini M, et al.: Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep 2009; 21: 1359-1366.
5. Lasota J, Miettinen M,: Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008; 53: 245-266.
6. Heinrich MC, Owzar K, Corless CL, et al.: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008; 26: 5360-5367.
7. Debiec-Rychter M, Sciot R, Le Cesne A, et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103. (Pubitemid 44275331)
8. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-4349. (Pubitemid 46621810)
9. Liegl B, Kepten I, Le C, et al.: Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216: 64-74.
10. Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-1338. (Pubitemid 44528723)
11. Heinrich MC, Maki RG, Corless CL, et al.: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008; 26: 5352-5359.
12. Prenen H, Cools J, Mentens N, et al.: Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006; 12: 2622-2627.
13. Prenen H, Guetens G, de Boeck G, et al.: Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006; 77: 11-16.
14. Blay JY, Casali PG, Reichardt P, et al.: A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update. J Clin Oncol 2008; 26: 10553.
15. Montemurro M, Schoffski P, Reichardt P, et al.: Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer 2009; 45: 2293-22297.
16. Nishida T, Sawaki A, Doi T, et al.: Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. J Clin Oncol 2010; 28: 10015.
17. Reichardt P, Blay J, Gelderblom H, et al.: Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3. J Clin Oncol 2010; 28: 10017.
18. Casali PG, Joensuu H, Martin Broto, et al.: Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). J Clin Oncol 2010; 28: TPS332.
19. Dubreuil P, Letard S, Ciufolini M, et al.: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009; 4: e7258.
20. Soria JC, Massard C, Magne N, et al.: Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. Eur J Cancer 2009; 45: 2333-22341.
21. Le Cesne A, Blay JY, Bui BN, et al.: Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer 2010; 46: 1344-1351.
22. Tokarski JS, Newitt JA, Chang CY, et al.: The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66: 5790-5797. (Pubitemid 43927133)
23. Schittenhelm MM, Shiraga S, Schroeder A, et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473-481. (Pubitemid 43166056)
24. Dewaele B, Wasag B, Cools J, et al.: Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008; 14: 5749-5758.
25. Imamura M, Yamamoto H, Nakamura N, et al.: Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol 2007; 20: 529-537. (Pubitemid 46631995)
26. Wang TB, Qiu WS, Wei B, et al.: Serum vascular endothelial growth factor and angiogenesis are related to the prognosis of patients with gastrointestinal stromal tumors. Ir J Med Sci 2009; 178: 315-320.
27. Guida T, Anaganti S, Provitera L, et al.: Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res 2007; 13: 3363-3369. (Pubitemid 46944924)
28. Wiebe L, Kasza K, Maki R, et al.: Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium. J Clin Oncol 2008; 26: 553s.
29. Reichardt P, Montemurro M, Gelderblom H, et al.: Sorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysis. J Clin Oncol 2009; 27: 10564.
30. Polverino A, Coxon A, Starnes C, et al.: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66: 8715-8721. (Pubitemid 44449188)
31. Caenepeel S, Renshaw-Gegg L, Baher A, et al.: Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. J Exp Clin Cancer Res 2010; 29: 96.
32. Coxon A, Bush T, Saffran D, et al.: Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin Cancer Res 2009; 15: 110-118.
33. Benjamin RS, Schoffski P, Hartmann JT, et al.: Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol 2010; Sep 14. [Epub ahead of print].
34. Wood JM, Bold G, Buchdunger E, et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178-2189. (Pubitemid 30225181)
35. Joensuu H, De Braud F, Coco P, et al.: Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008; 19: 173-177.
36. Fumo G, Akin C, Metcalfe DD, et al.: 17-Allylamino-17- demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004; 103: 1078-1084. (Pubitemid 38129574)
37. Matei D, Satpathy M, Cao L, et al.: The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem 2007; 282: 445-453. (Pubitemid 47076653)
38. Bauer S, Yu LK, Demetri GD, et al.: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006; 66: 9153-9161. (Pubitemid 44521135)
39. Wagner AJ, Morgan JA, Chugh R, et al.: Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol 2008; 26: 10503.
40. Bauer S, Duensing A, Demetri GD, et al.: KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene 2007; 26: 7560-77568.
41. Kondapaka SB, Singh SS, Dasmahapatra GP, et al.: Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103.
42. Conley AP, Araujo D, Ludwig J, et al.: A randomized phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST. J Clin Oncol 2009; 27: 10563.
43. Godwin AK, Rink L, Chi T, et al.: Insulin-like growth factor 1 receptor (IGF-1R): A potential therapeutic target for gastrointestinal stromal tumors (GIST. J Clin Oncol 2008; 26: 10507.
44. Schoffski P, Reichardt P, Blay JY, et al.: A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol 2010; 21: 1990-11998.
45. Hohenberger P, Bauer S, Gruenwald V, et al.: Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST. J Clin Oncol 2010; 28: 10048.